Gilead, Precision to co-develop hepatitis B therapies
Gilead and Precision BioSciences are to work together on developing gene-editing treatments against hepatitis B.
Read More
Tag: ARCUS
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
